Tofacitinib vs placebo
Failure to maintain clinical response · Patients with quiescent ulcerative colitis
Tofacitinib leads to lower failure to maintain clinical response (5 mg/10 mg) compared with placebo (high certainty).
1 finding from 1 review
- Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes onlyRR 0.54 [0.47, 0.62]1 study · 593 participantsHigh